Holen Sie sich die Stockscreener-App
2.06
0.98%
0.02
Cadrenal Therapeutics Inc Aktie (CVKD) Neueste Nachrichten
Cadrenal Therapeutics Inc (CVKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cadrenal Therapeutics Inc (CVKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cadrenal Therapeutics Inc (CVKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cadrenal Therapeutics Inc (CVKD) Institutional Confidence - TradingKey
Cadrenal Therapeutics Inc (CVKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:2.040|Chg%:+0.010 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Cadrenal Therapeutics Inc (CVKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cadrenal Therapeutics Market Sentiment - Benzinga España
Cadrenal Therapeutics, Inc. Revenue Breakdown – NASDAQ:CVKD - TradingView
CVKD|Cadrenal Therapeutics Inc|Price:2.030|Chg%:-0.010 - TradingKey
Form PRE 14A CADRENAL THERAPEUTICS For: 23 July By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (NASDAQ: CVKD) seeks approval for 1M-share equity plan and 960K warrant shares - Stock Titan
H.C. Wainwright Maintains Cadrenal Therapeutics(CVKD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cadrenal Therapeutics, Inc. SEC Filing (Jul 21, 2026) - Stock Titan
Cadrenal Therapeutics Launches Cardiac Acute Care Franchise Strategy - TipRanks
Cadrenal seeks partners for cardiac care drug portfolio - Investing.com
Cadrenal seeks partners for cardiac care drug portfolio By Investing.com - Investing.com Canada
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation - The Manila Times
Cadrenal's Phase 2 data show >25% absolute reduction in clotting events - Stock Titan
Cadrenal Therapeutics Announces Chief Medical Officer Transition - TipRanks
Cadrenal Therapeutics (NASDAQ: CVKD) outlines CMO Ferguson's exit deal - Stock Titan
Cadrenal Therapeutics (CVKD) Edges Lower Amid Mixed Sentiment, Holding Above Key SupportResistance Breakout Stocks - dars.gov.et
Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing - Stock Titan
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
CADRENAL THERAPEUTICSNO SERIOUS ADVERSE EVENTS OR DEATHS REPORTED WITH CAD-1005 IN PHASE 2 TRIAL - webull.com
Form S-3 Cadrenal Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (NASDAQ: CVKD) files resale for 2.94M warrant shares - Stock Titan
Cadrenal presents phase 2 data for CAD-1005 at ISTH congress - Investing.com Nigeria
Cadrenal presents phase 2 data for CAD-1005 at ISTH congress By Investing.com - Investing.com South Africa
Cadrenal Therapeutics Presents Positive Phase 2 CAD-1005 Data in Late-Breaking ISTH Oral Presentation for Heparin-Induced Thrombocytopenia - Quiver Quantitative
Experimental CAD-1005 drug cuts serious blood clots in HIT patients by over 25% - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
CVKD Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Preclinical ProgressEarnings Cycle Report - dars.gov.et
Cadrenal Therapeutics Announces Chief Medical Officer Resignation - TipRanks
Cadrenal Therapeutics (CVKD) Chief Medical Officer James Ferguson to step down July 31, 2026 - Stock Titan
Cadrenal Therapeutics, Inc. Announces Resignation of James J. Ferguson III from Chief Medical Officer Role, Effective July 31, 2026 - marketscreener.com
Cadrenal Therapeutics (CVKD) Declines 5.67% as Stock Tests Key Support at $3.00Weak Sell Signals - DonanımHaber
CVKD Q1 2026 Earnings: Narrower-than-expected loss drives positive market reactionEarnings Weakness Phase - dars.gov.et
Cadrenal Therapeutics (CVKD) Stock Analysis Report | Financials & Insights - Benzinga
Cadrenal Therapeutics Secures Private Placement to Extend Runway - The Globe and Mail
Cadrenal Therapeutics CEO sells $22,422 in stock By Investing.com - Investing.com India
Cadrenal (CVKD) CEO sells 7,400 shares, retains direct and trust stakes - Stock Titan
Cadrenal Therapeutics CEO sells $22,422 in stock - Investing.com UK
Form 4 Cadrenal Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
(CVKD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants - TradingView
Cadrenal Therapeutics (NASDAQ: CVKD) lines up up to $8.8M via private placement - Stock Titan
Cadrenal Therapeutics Enters Upto $8.8 Mln Private Placement To Extend Cash Runway; Stock Down - RTTNews
Cadrenal raises $3M now, with $5.8M more possible from warrants - Stock Titan
Cadrenal Therapeutics raises $3 million in private placement - Investing.com
Cadrenal Therapeutics raises $3 million in private placement By Investing.com - Investing.com Australia
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):